Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies

Hyeok Choi, Sung Soo Ahn, Jason Jungsik Song, Yong Beom Park, Jaewoo Song, Sang Won Lee

Research output: Contribution to journalArticle

Abstract

We investigated the overall frequency of anti-phospholipid syndrome (APS) occurrence in Korean patients with consecutively detected anti-phospholipid antibodies with an interval of 12 weeks (persistent aPLs). We retrospectively reviewed the results of blood tests of aPLs in 14,889 patients in whom aPL tests were performed at Yonsei University College of Medicine, Severance Hospital, from January 2012 to August 2018, and included 833 patients with persistent aPLs. We obtained clinical and laboratory data including anti-cardiolipin antibodies IgM and IgG, anti-beta2 glycoprotein1 IgM and IgG, and lupus anticoagulant (LAC). Of 833 patients with persistent aPLs, 96 patients (11.5%) had APS (84 patients had thrombotic events and 12 had pregnancy morbidity). Among aPLs, LAC was detected in patients with APS more frequently than asymptomatic carriers of aPLs (46.9% vs. 25.9%, p < 0.001). Patients with LAC (relative risk (RR) 2.558, p < 0.001) and aPLs ≥ 2 (RR 1.731, p = 0.014) exhibited the higher rate of APS occurrence than those without. Moreover, patients with aPLs ≥ 3 and aPLs ≥ 4 exhibited the higher rates of APS occurrence than those without (RR 2.753, p < 0.001 and RR 3.209, p = 0.013). Meanwhile, patients with ANA, anti-dsDNA, anti-SSA/Ro, and SLE exhibited the increased frequency of LAC positivity, compared to those without (RR 3.304, p = 0.005, RR 4.269, p = 0.032, RR 3.750, p = 0.041 and RR 8.828, p < 0.001, respectively). APS occurs in 11.5% of Korean patients with persistent aPLs. LAC positivity and aPLs ≥ 2 were significantly associated with APS occurrence. SLE and SLE-related autoantibodies were associated with LAC positivity.

Original languageEnglish
Pages (from-to)1359-1367
Number of pages9
JournalRheumatology International
Volume39
Issue number8
DOIs
Publication statusPublished - 2019 Aug 1

Fingerprint

Antiphospholipid Syndrome
Anti-Idiotypic Antibodies
Phospholipids
Lupus Coagulation Inhibitor
Hospital Medicine
Cardiolipins
Hematologic Tests
Autoantibodies
Immunoglobulin M
Immunoglobulin G
Morbidity

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Choi, Hyeok ; Ahn, Sung Soo ; Song, Jason Jungsik ; Park, Yong Beom ; Song, Jaewoo ; Lee, Sang Won. / Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies. In: Rheumatology International. 2019 ; Vol. 39, No. 8. pp. 1359-1367.
@article{892b371191414933b907e9d78b4aaba2,
title = "Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies",
abstract = "We investigated the overall frequency of anti-phospholipid syndrome (APS) occurrence in Korean patients with consecutively detected anti-phospholipid antibodies with an interval of 12 weeks (persistent aPLs). We retrospectively reviewed the results of blood tests of aPLs in 14,889 patients in whom aPL tests were performed at Yonsei University College of Medicine, Severance Hospital, from January 2012 to August 2018, and included 833 patients with persistent aPLs. We obtained clinical and laboratory data including anti-cardiolipin antibodies IgM and IgG, anti-beta2 glycoprotein1 IgM and IgG, and lupus anticoagulant (LAC). Of 833 patients with persistent aPLs, 96 patients (11.5{\%}) had APS (84 patients had thrombotic events and 12 had pregnancy morbidity). Among aPLs, LAC was detected in patients with APS more frequently than asymptomatic carriers of aPLs (46.9{\%} vs. 25.9{\%}, p < 0.001). Patients with LAC (relative risk (RR) 2.558, p < 0.001) and aPLs ≥ 2 (RR 1.731, p = 0.014) exhibited the higher rate of APS occurrence than those without. Moreover, patients with aPLs ≥ 3 and aPLs ≥ 4 exhibited the higher rates of APS occurrence than those without (RR 2.753, p < 0.001 and RR 3.209, p = 0.013). Meanwhile, patients with ANA, anti-dsDNA, anti-SSA/Ro, and SLE exhibited the increased frequency of LAC positivity, compared to those without (RR 3.304, p = 0.005, RR 4.269, p = 0.032, RR 3.750, p = 0.041 and RR 8.828, p < 0.001, respectively). APS occurs in 11.5{\%} of Korean patients with persistent aPLs. LAC positivity and aPLs ≥ 2 were significantly associated with APS occurrence. SLE and SLE-related autoantibodies were associated with LAC positivity.",
author = "Hyeok Choi and Ahn, {Sung Soo} and Song, {Jason Jungsik} and Park, {Yong Beom} and Jaewoo Song and Lee, {Sang Won}",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s00296-019-04318-4",
language = "English",
volume = "39",
pages = "1359--1367",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "8",

}

Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies. / Choi, Hyeok; Ahn, Sung Soo; Song, Jason Jungsik; Park, Yong Beom; Song, Jaewoo; Lee, Sang Won.

In: Rheumatology International, Vol. 39, No. 8, 01.08.2019, p. 1359-1367.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies

AU - Choi, Hyeok

AU - Ahn, Sung Soo

AU - Song, Jason Jungsik

AU - Park, Yong Beom

AU - Song, Jaewoo

AU - Lee, Sang Won

PY - 2019/8/1

Y1 - 2019/8/1

N2 - We investigated the overall frequency of anti-phospholipid syndrome (APS) occurrence in Korean patients with consecutively detected anti-phospholipid antibodies with an interval of 12 weeks (persistent aPLs). We retrospectively reviewed the results of blood tests of aPLs in 14,889 patients in whom aPL tests were performed at Yonsei University College of Medicine, Severance Hospital, from January 2012 to August 2018, and included 833 patients with persistent aPLs. We obtained clinical and laboratory data including anti-cardiolipin antibodies IgM and IgG, anti-beta2 glycoprotein1 IgM and IgG, and lupus anticoagulant (LAC). Of 833 patients with persistent aPLs, 96 patients (11.5%) had APS (84 patients had thrombotic events and 12 had pregnancy morbidity). Among aPLs, LAC was detected in patients with APS more frequently than asymptomatic carriers of aPLs (46.9% vs. 25.9%, p < 0.001). Patients with LAC (relative risk (RR) 2.558, p < 0.001) and aPLs ≥ 2 (RR 1.731, p = 0.014) exhibited the higher rate of APS occurrence than those without. Moreover, patients with aPLs ≥ 3 and aPLs ≥ 4 exhibited the higher rates of APS occurrence than those without (RR 2.753, p < 0.001 and RR 3.209, p = 0.013). Meanwhile, patients with ANA, anti-dsDNA, anti-SSA/Ro, and SLE exhibited the increased frequency of LAC positivity, compared to those without (RR 3.304, p = 0.005, RR 4.269, p = 0.032, RR 3.750, p = 0.041 and RR 8.828, p < 0.001, respectively). APS occurs in 11.5% of Korean patients with persistent aPLs. LAC positivity and aPLs ≥ 2 were significantly associated with APS occurrence. SLE and SLE-related autoantibodies were associated with LAC positivity.

AB - We investigated the overall frequency of anti-phospholipid syndrome (APS) occurrence in Korean patients with consecutively detected anti-phospholipid antibodies with an interval of 12 weeks (persistent aPLs). We retrospectively reviewed the results of blood tests of aPLs in 14,889 patients in whom aPL tests were performed at Yonsei University College of Medicine, Severance Hospital, from January 2012 to August 2018, and included 833 patients with persistent aPLs. We obtained clinical and laboratory data including anti-cardiolipin antibodies IgM and IgG, anti-beta2 glycoprotein1 IgM and IgG, and lupus anticoagulant (LAC). Of 833 patients with persistent aPLs, 96 patients (11.5%) had APS (84 patients had thrombotic events and 12 had pregnancy morbidity). Among aPLs, LAC was detected in patients with APS more frequently than asymptomatic carriers of aPLs (46.9% vs. 25.9%, p < 0.001). Patients with LAC (relative risk (RR) 2.558, p < 0.001) and aPLs ≥ 2 (RR 1.731, p = 0.014) exhibited the higher rate of APS occurrence than those without. Moreover, patients with aPLs ≥ 3 and aPLs ≥ 4 exhibited the higher rates of APS occurrence than those without (RR 2.753, p < 0.001 and RR 3.209, p = 0.013). Meanwhile, patients with ANA, anti-dsDNA, anti-SSA/Ro, and SLE exhibited the increased frequency of LAC positivity, compared to those without (RR 3.304, p = 0.005, RR 4.269, p = 0.032, RR 3.750, p = 0.041 and RR 8.828, p < 0.001, respectively). APS occurs in 11.5% of Korean patients with persistent aPLs. LAC positivity and aPLs ≥ 2 were significantly associated with APS occurrence. SLE and SLE-related autoantibodies were associated with LAC positivity.

UR - http://www.scopus.com/inward/record.url?scp=85065728033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065728033&partnerID=8YFLogxK

U2 - 10.1007/s00296-019-04318-4

DO - 10.1007/s00296-019-04318-4

M3 - Article

C2 - 31076830

AN - SCOPUS:85065728033

VL - 39

SP - 1359

EP - 1367

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 8

ER -